5, Blossom St

Boston,

MA,

USA,

ZIP: 02114

Phone: (+1) 617 455 4188

With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients' lives.

The 2nd Rare CNS and Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.

Tightly focused on industry progress, join stakeholders exploring ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes in at this unique drug sponsor conference.

Don't miss out on the industry's definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers, emerging therapeutic targets and translational biology

If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

URLs:
Tickets: https://go.evvnt.com/1289306-2?pid=1052 
Brochure: https://go.evvnt.com/1289306-3?pid=1052

Prices:
Industry Pricing - Conference + Workshop Day: USD 4096.00,
Industry Pricing - Conference Only: USD 2599.00,
Service and Solution Provider Pricing - Conference + Workshop Day: USD 5846.00,
Service and Solution Provider Pricing - Conference Only: USD 3599.00

Alfica Sehgal, Senior Vice President, Head of Discovery and Translation, CAMP4 Therapeutics, Allyson Berent, Chief Scientific Officer, Foundation for Angelman Syndrome Therapeutics (FAST), Alysson Murotri, Professor, UC San Diego Stem Cell Program, Andrew Young, Director, Sangamo, Brian Harvey, Scientist, Biogen, Bruce Bloom, Chief Collaboration Officer, Healx, Christopher U Missling, President and Chief Executive Officer, Anavex Life Science Corp, Daniel Lavery, Chief Scientific Officer, Loulou Foundation, Elizabeth Berry-Kravis, Professor, Rush University Medical Center, Erin Rosenbaugh, Scientific Project Manager, FNIH, Gopi Shanker, Chief Scientific Officer, Tevard Biosciences, Heather Lau, Executive Director Global Clinical Development, Ultragenyx, Holly Kordasiewicz, Vice President Neurology Research, Ionis Pharmaceuticals, Jana Von Hehn, Chief Scientific Officer, Rett Syndrome Research Trust, Jennifer Panagoulias, Regulatory Affairs and Compliance Professional, Angelman Syndrome Biomarker and Outcome Measure Consortium, Leonard Abbeduto, Director and Professor, MIND Institute, Psychiatry and Behavioural Sciences, University of California, Davis, Luke Rosen, Founder, KIF1A.ORG, Lynn-Allison, Durham Founder and Chief Executive Officer, STALICLA, Massimillio Bianchi, Founder, President and Chief Executive Officer, Ulysses, Onno Faber, Chief Executive Officer, Rarebase, Paulina Rychenkova, Founder, CureSHANK, Rachael Hawtin, Executive Director, Clinical Biomarker Development and Strategy, Ultragenyx, Robert Ring, Chief Scientific Officer, Kaerus Bioscience, Sam Benezra, Scientist, Biogen, Samir Koirala, Director, Biogen, Sarah Glass, Chief Operating Officer, n-Lorem Foundation, Susanne Clinch, Principal Patient Centered Outcomes Research Scientist, Roche, Tracy Cole, Senior Director, Research and Development, n-Lorem, Wesley Horton, Senior Project Manager, FNIH, Xavier Liogier, Chief of Translational Science, Loulou Foundation, Yael Weiss, Chief Executive Officer, Mahzi Therapeutics